Last mentioned: Mar 3, 2026
Product Expansion
Anticipated updates to the MX908 handheld platform for forensic use.
Q4 Earnings Release
908 Devices reports top and bottom-line beats.
FY26 Guidance Introduced
Company provides long-term financial targets for the first time.
Bioprocessing Integration
Targeted milestone for ZipChip adoption in major biopharma workflows.
908 Devices (MASS) reported a strong Q4, beating both top and bottom-line estimates and introducing a positive FY26 outlook. The results signal a recovery in the life sciences tools sector, driven by the adoption of point-of-need mass spectrometry in bioprocessing and forensics.
This page surfaces every story mentioning EVgo across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where EVgo was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |